Autolus Therapeutics (NASDAQ:AUTL) Posts Earnings Results, Misses Expectations By $0.10 EPS

Autolus Therapeutics (NASDAQ:AUTL) announced its quarterly earnings data on Tuesday. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10), Zacks reports. During the same period last year, the company earned ($0.26) EPS.

Autolus Therapeutics Trading Down 1.2 %

Shares of Autolus Therapeutics stock opened at $3.29 on Thursday. The stock has a market cap of $875.44 million, a P/E ratio of -2.72 and a beta of 2.04. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. Autolus Therapeutics has a 12-month low of $3.06 and a 12-month high of $7.45. The business’s 50 day moving average is $3.95 and its 200-day moving average is $4.00.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.